Labionyx was recently founded by a group of scientists and engineers to benefit humanity with the latest technological advances in point of care biodetection. Labionyx believes that the combination of integrated optics and microfluidic technologies is the best strategy for the development of highly sensitive, fast response miniaturized point of care biosensors. The applications for these biosensing devices are endless. However, currently our company focus on the development of point of care optical biosensors for early detection of breast cancer and rapid detection of COVID-19.
Indeed, an early detection of cancer is essential to prevent a late treatment of the disease which could be fatal. We believe our technology is sensitive enough to detect signs of the early stage of breast cancer and will provide a widespread and easy way to detect early signs of cancer at home or at the clinic. The same device with few biochemical modifications could also be used for early detection of other common cancers such as lung and prostate cancers.
To address the current pandemic, the same core technology will be used to build a quick and easy-to-use device for the detection of SARS-COV-2, the virus responsible for COVID-19, with a small sample of saliva. The device would be paired with an application on the smartphone of the patient that will communicate with the healthcare network to monitor and contain the spread of the virus.